SNGX Key Statistics, Chart & Performance
The current stock price of SNGX is 1.4 USD. In the past month the price increased by 1.45%. In the past year, price decreased by -45.31%.
SNGX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SNGX. When comparing the yearly performance of all stocks, SNGX is a bad performer in the overall market: 88.39% of all stocks are doing better.
SNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNGX. The financial health of SNGX is average, but there are quite some concerns on its profitability.
SNGX Financial Highlights
Over the last trailing twelve months SNGX reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 58.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.45% | ||
| ROE | -150.79% | ||
| Debt/Equity | 0 |
SNGX Forecast & Estimates
7 analysts have analysed SNGX and the average price target is 17.85 USD. This implies a price increase of 1175% is expected in the next year compared to the current price of 1.4.
For the next year, analysts expect an EPS growth of 64.11% and a revenue growth -100% for SNGX
SNGX Ownership
About SNGX
Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Company Info
SOLIGENIX INC
29 Emmons Drive, Suite B-10
Princeton NEW JERSEY 08540 US
CEO: Christopher J. Schaber
Employees: 14
Phone: 16095388200
SOLIGENIX INC / SNGX FAQ
Can you describe the business of SOLIGENIX INC?
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
What is the stock price of SOLIGENIX INC today?
The current stock price of SNGX is 1.4 USD. The price increased by 1.45% in the last trading session.
Does SNGX stock pay dividends?
SNGX does not pay a dividend.
How is the ChartMill rating for SOLIGENIX INC?
SNGX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in SOLIGENIX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNGX.
What is the expected growth for SNGX stock?
The Revenue of SOLIGENIX INC (SNGX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for SNGX stock?
SOLIGENIX INC (SNGX) currently has 14 employees.